CoChat

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study

Adinolfi, Luigi Elio, Petta, Salvatore, Fracanzani, Anna Ludovica, Coppola, Carmine, Narciso, Vincenzo, Nevola, Riccardo, Rinaldi, Luca, Calvaruso, Vincenza, Staiano, Laura, Di Marco, Vito, Marrone, Aldo, Pafundi, Pia Clara, Solano, Antonio, Lombardi, Rosa, Sasso, Ferdinando Carlo, Saturnino, Mariarosaria, Rini, Francesca, Guerrera, Barbara, Troina, Graziano, Giordano, Mauro, Craxì, Antonio · 2020 · Atherosclerosis
Cited by 98

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS HCV is associated with an increased risk of cardiovascular events (CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease is poorly understood. We investigate whether HCV eradication reduces CV events. METHODS In a prospective multicentre study, 2204 HCV patients (F0-F2:29.5%, F3-F4: 70.5%) were enrolled. Males were 48%, median age was 68 (59-74) years and BMI 25.9 (23.1-28); 24.7% were smokers, 18% had diabetes, 13.2% had cholesterol levels >200 mg/dl and 9.1% took statins, 44% had hypertension. During an overall median follow-up of 28 (24-39) months, incident CV events, such as ischemic heart disease (IHD) and ischemic cerebral stroke (ICS), were recorded. An overall of 2204 patients were evaluated as control group and 1668 patients after HCV elimination were followed as a case group. Factors associated with CV events were evaluated by uni- and multi-variate analyses. RESULTS Incident CV rates per 100 patient years in pre-treatment and untreated controls and treated cases were 1.12, 1.14 and 0.44 (p = 0.0001 vs. controls), respectively, and a decreased of relative risk (RR = 0.379; p = 0.0002) was observed. CV risk was 2.0-3.5 times lower then in controls (HR 3.671; 95%C.I.:1.871-7.201; p < 0.001). The calculated number of patients to be treated to get a benefit in a patient was 55.26. The annual incidence reduction of CV events was 0.68%. HCV clearance was independently associated with CV events reduction (OR, 4.716; 95% C.I.:1.832-12.138; p = 0.001). CONCLUSIONS HCV clearance by DAA reduces CV events (IHD and ICS) with both clinical and socio-economic benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2020.01.010

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 98

Metadata

Authors
Adinolfi, L. E., Petta, S., Fracanzani, A. L., Coppola, C., Narciso, V., Nevola, R., Rinaldi, L., Calvaruso, V., Staiano, L., Di Marco, V., Marrone, A., Pafundi, P. C., Solano, A., Lombardi, R., Sasso, F. C., Saturnino, M., Rini, F., Guerrera, B., Troina, G., Giordano, M., & Craxì, A.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2020-03
Volume
296
Pages
40-47
ISSN
0021-9150 (ISSN-L)
OpenAlex
W3000488526
Cited by
98
References
4
FWCI
10.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2020.01.010
The paper
Adinolfi, L. E., Petta, S., Fracanzani, A. L., Coppola, C., Narciso, V., Nevola, R., Rinaldi, L., Calvaruso, V., Staiano, L., Di Marco, V., Marrone, A., Pafundi, P. C., Solano, A., Lombardi, R., Sasso, F. C., Saturnino, M., Rini, F., Guerrera, B., Troina, G., . . . Craxì, A. (2020). Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2020.01.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.